Human evidence includes early PK/GH-response studies and a randomized Phase II postoperative-ileus trial. In that trial, IV ipamorelin 0.03 mg/kg twice daily did not significantly improve the primary or key secondary efficacy endpoints versus placebo.
Regulatory status
Not FDA-approved; FDA lists safety concerns for compounded ipamorelin.
Main limitations
Muscle gain, fat loss, recovery, anti-ageing benefit, safe chronic subcutaneous use or a validated wellness dose.
Safety
FDA notes immunogenicity/impurity concerns and serious adverse events in an IV gastric-motility study, including deaths, with insufficient information for other injection uses.
i
Human evidence includes early PK/GH-response studies and a randomized Phase II postoperative-ileus trial. In that trial, IV ipamorelin 0.03 mg/kg twice daily did not significantly improve the primary or key secondary efficacy endpoints versus placebo.
What the evidence actually supports
✓Do not translate an acute GH response directly into claims about physique or recovery.
✓Add a distinct 'what the GH pulse does not prove' record.
✓This sits beside the PK/GH-pulse study and shows why target engagement is not clinical benefit.
✓Use regulator-attributed wording and keep route-specific.
What is not established / key limitations
×No established lifestyle outcome such as muscle gain, fat loss, recovery or anti-ageing.
×No controlled evidence identified for muscle gain, fat loss, injury recovery or anti-ageing outcomes.
×Primary endpoint P=0.15; no significant key/secondary efficacy benefit.
Median time was 25.3 hours with ipamorelin versus 32.6 hours placebo; difference was not statistically significant (P=0.15). Key and secondary efficacy analyses were not significant.
FDA notes immunogenicity/impurity concerns and serious adverse events in an IV gastric-motility study, including deaths, with insufficient information for other injection uses.
FDA cites serious adverse events in the IV clinical programme and says adequate safety information for other injectable routes is lacking; compounded-product impurity and immunogenicity issues also matter.
Technical details
Mechanism / biologyAgonist at the growth-hormone secretagogue receptor, producing a pulse of GH release.
Route / formulation boundaryThe Phase II evidence was intravenous in postoperative patients and cannot be transferred to subcutaneous wellness/bodybuilding use.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusVerified dosing evidence added. Published human pharmacology regimen. See dosing_evidence records for route, regimen, population, duration and source.
Identifiers & alternate namesIPA
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
